1. Patanjali Foods:
This edible-oil company fell 4.8% on November 16 after Q2FY27 net profit dropped 18.8% YoY. Revenue climbed 15.6%, yet higher input costs and tighter margins hurt profitability.
In September, the government cut taxes on imported edible oil. Patanjali had already bought its oil earlier at higher prices. When cheaper new imports arrived, market prices dropped, leaving the company with costlier older stock. This squeeze pulled its operating profit margin (EBITDA) down from 5.2% in the previous quarter to 3%.
However, management moved quickly to defend profits. Patanjali kept some imported oil on ships and in port warehouses instead of clearing customs early. That way, it didn't incur taxes upfront and paid the lower rate only when bringing the oil to market. In staples, the company cut back on low-margin sales where it couldn't pass rising costs to buyers. Staples revenue dropped 24.4% QoQ, shrinking its share of total sales from 9.8% to 7.4%.
Patanjali is also expanding its oil palm business to reduce reliance on imported oils. This business generated about 6.6% of company revenue. Currently, only about a third of its 1.3 lakh hectares produce peak yields. Nearly two-thirds remain young or immature, including 57% under three years old. Management anticipates output and profits to climb as existing plantations mature and cultivation expands.
Management expects a stronger H2FY27 as Q2 hurdles fade. Last quarter, a 13% monsoon shortfall cooled rural demand, while a late festive calendar shifted September purchases into October. CEO Sanjeev Asthana said, “With the recent festive season and the upcoming wedding season, we expect growth momentum to continue.” Patanjali also expects edible-oil EBITDA margins to rebound from 3% in Q2 to around 4% in H2.
Jefferies maintains its 'Buy' rating with a Rs 550 target price and a 36.1% upside, even as it cuts FY27 earnings estimates by 19% and FY28–29 forecasts by 4–6%. Despite near-term pressure, the brokerage expects profit to grow around 21% annually over FY27–29 as food margins improve and higher-margin consumer businesses expand.
2. Amber Enterprises India:
This consumer electronics manufacturer surged 7.4% on November 19 as copper prices tumbled to a seven-month low, dropping over 20% from recent peaks. This sharp decline significantly improves the company’s margin outlook as copper accounts for nearly half of its raw material costs. The copper sell-off was fueled by doubts over AI spending, fading expectations of US tariffs on the metal, and a strengthening dollar.
Ventura’s Research Head Vinit Bolinjkar noted that brands, having raised prices earlier this year, now face easing input pressures. He added, “Amber offers a compelling play, benefiting from stronger original equipment manufacturer order volumes alongside a multi-year growth catalyst from foray into the high-margin bare printed circuit board (PCB) manufacturing.”
The margin pressure currently facing Amber showed clearly in its Q2FY27 results. Revenue surged 60% YoY, beating Forecaster estimates, driven by strong demand for consumer durables and electronics. However, net loss expanded 144% due to soaring input, inventory, staff, and finance costs, contrary to the estimates of a Rs 2 crore profit.
Segment performance proved robust. The electronics division’s (47.5% of total revenue) sales surged 94% as previous price hikes took effect. The consumer durables segment’s (47.6% of revenue) topline grew 41% due to strong commercial AC sales and new efficiency norms. However, EBITDA margin dropped 180 bps, hurt by lower railways profitability, commodity inflation, and new plant startup expenses.
Management plans to tackle these margin concerns by improving its business mix and launching its PCB manufacturing plant. CFO Sudhir Goel outlined the investment roadmap, saying, “We expect a capex of Rs 1,800-2,000 crore for FY27 and FY28, each.”
The company is already ramping up production at its new Faridabad facility and plans to launch PCB operations by the first half of 2027. Additionally, a new subsidiary targeting smartphone manufacturing for brands like Oppo, Realme, and OnePlus will begin production in Q1FY28, aiming for 80 lakh units in its first year and 1.6 crore units in the second.
Following these developments, ICICI Direct retained its ‘Buy’ rating with a target price of Rs 7,500, implying an 11.3% upside. The brokerage expects margins to improve as commodity inflation fades and new investments drive operational leverage. Analysts project the company to deliver annual revenue growth of 43% and net profit growth of 82% through FY28.
3. Kaynes Technology India:
The stock of this electrical equipment & products company fell over 16% in the past week after posting a weak second quarter. Q2 net profit plunged 19.5% QoQ to Rs 45.4 crore, weighed down by higher raw material, employee benefit, and finance costs. Meanwhile, revenue edged up marginally by 1.1% to Rs 952.5 crore, supported by steady traction in its automotive and railway segments. The company appears on a screener of stocks with expensive valuations according to the Trendlyne Valuation Score.
Revenue growth was largely held back by a deliberate pullback in the smart metering business, where revenue dropped roughly 76% YoY to Rs 54 crore. Excluding metering, the core Electronics Manufacturing Services (EMS) business surged 34% to Rs 799 crore, driven by strong demand across aerospace and defence, railways, and industrial verticals. Meanwhile, operating margins came under pressure from elevated copper, aluminium, and crude-linked input prices, as well as rupee depreciation and initial facility ramp-up expenses.
MD Muthukumar Narayanaswami outlined plans to retain smart meter manufacturing while offloading installation and operations & maintenance (O&M) to a third party. Slated for completion by February 2027, this strategic scale-down aims to unlock roughly Rs 1,000 crore in receivables and pare down debt. As inventory levels ease, management expects the company to turn cash flow positive over the next 3 to 4 quarters.
Offsetting the muted quarterly numbers was a major strategic milestone on November 12, when subsidiary Kaynes Semicon partnered with Vishay Intertechnology and Ecomal Nederland to form a joint venture. Under the proposed deal, Vishay will acquire a 49% equity stake in Kaynes Semicon, which will provide post-fab wafer processing, assembly, testing, and packaging services. Vishay is expected to utilize 75% to 90% of the facility's capacity, opening access to global markets outside China and accelerating commercialization, with definitive agreements expected within 2 to 3 months.
Motilal Oswal maintained its ‘Buy’ rating on the stock with a target price of Rs 3,100. Despite the soft Q2 performance, the brokerage highlighted a robust order book of Rs 10,600 crore. Analysts expect Q3 to remain muted before a healthy rebound in Q4, driven by the ramp-up of OSAT and PCB operations alongside sustained momentum in the core EMS business.
4. Laurus Labs:
The stock of this pharmaceuticals company rose over 4% on November 17 after CEO and promoter Satyanarayana Chava ruled out further stake sales. He clarified that the promoter group's recent sale of 20.7 lakh shares on November 11, worth roughly Rs 500 crore, was solely meant to clear personal debt and fund philanthropic initiatives.
Reaffirming confidence in the business, Chava highlighted Laurus Labs' evolution into a fully integrated CDMO player backed by strong operational momentum. The company plans Rs 2,000 crore in capex for FY27, scaling to over Rs 3,000 crore in FY28, entirely funded by internal cash flows without straining the balance sheet. Despite these heavy investments, gross and EBITDA margins are projected to stay steady over the coming quarters, with no expected dilution in return ratios.
The firm delivered a standout Q2FY27, with revenue climbing 32.1% YoY to Rs 2,219.4 crore. Growth was anchored by the CDMO division, which contributed a leading 39% of net revenue, propelled by newly commissioned assets. The stock features on a screener of companies that have outperformed their industry over the past month.
Management noted that the CDMO pipeline continues to expand across both clinical and commercial programs, offering clear supply visibility over the next 18 to 24 months, while ruling out any major customer destocking.
ICICI Direct maintained its ‘Buy’ rating on the stock with a target price of Rs 2,550. The brokerage noted that its premium valuation is justified by its sustained capex push and consistent earnings delivery, though heavy reliance on the CDMO business remains a key monitorable risk.
5. Deepak Fertilisers & Petrochemicals:
This chemicals and fertiliser maker gained around 15% over the past week following its Q2FY27 results. Revenue increased 11% YoY, while net profit grew 84%. EBITDA margin expanded 706 basis points to 22.5%, marking a strong improvement in operating profitability. The company's integrated LNG-to-ammonia-to-downstream value chain is emerging as a key profitability driver.
A long-term LNG sourcing arrangement with Equinor supports its ammonia manufacturing operations, which feed into nitric acid and downstream products, including technical ammonium nitrate (TAN) and fertilisers. Higher in-house ammonia integration and a better product mix helped protect margins amid global supply disruptions. Chairman and MD S.C. Mehta said, “It is both a risk mitigator as well as a margin enhancer, and it is allowing us to capture value across the chain through the market cycles.”
The biggest growth catalyst is the commissioning of two major expansion projects at Gopalpur and Dahej. Both projects are around 98% complete and expected to commence operations in Q4FY27. The expansion will increase TAN capacity by around 60–70% and more than double annual nitric acid sales capacity. CFO Subhash Anand said, “The heavy lifting is behind us, and the company is entering a phase of accelerated monetisation as these projects become operational.”
Trendlyne Forecaster shows a consensus 'Strong Buy' rating from three analysts, implying around 29% upside. However, a slower recovery in fertiliser demand, raw-material inflation, and delays in commissioning or ramping up the new plants could affect earnings growth.
Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.